FRANKFURT (dpa-AFX Broker) – The study data for the cancer drug Pelabresib caused a lot of nervousness in MorphoSys shares on Tuesday morning. Recently the price slipped massively.
At their peak, they were traded 20 percent higher at just over 26 euros at broker Lang & Schwarz, and the evening before they were even traded at almost 30 euros in initial reactions. In Tradegate trading, however, the price recently turned negative at 18 percent. This marks a low since April.
Initial assessments from analysts painted a mixed picture. The company achieved an important primary endpoint with the active ingredient, but did not show any significant benefit in a secondary endpoint, wrote analyst James Gordon from JPMorgan in an initial assessment./bek/tih
———————-
dpa-AFX Broker – the trader news from dpa-AFX
———————-
Selected leveraged products on MorphoSys
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on MorphoSys
The leverage must be between 2 and 20
Advertising